期刊文献+

阿立哌唑治疗儿童孤独症与精神发育迟滞临床观察 被引量:14

Clinical observation of aripiprazole in treatment of autism and mental retardation
暂未订购
导出
摘要 目的:观察阿立哌唑治疗儿童孤独症和精神发育迟滞的多动及冲动等行为障碍的疗效及不良反应。方法:对48例儿童孤独症和精神发育迟滞,给予阿立哌唑治疗。疗程4周。在治疗前及治疗2、4周对其进行Conners父母量表评定,并观察不良反应。结果:治疗2周,品行问题、学习问题、心身障碍、冲动-多动、焦虑、多动等症状即有显著改善(P<0.001)。治疗4周改善更明显。不良反应少。结论:阿立哌唑能有效治疗精神发育迟滞和儿童孤独症的冲动及多动行为,不良反应少。 Objective: To observe the efficacy and side effects of aripiprazole in the treatment of autism or mental retardation in child and adolescent. Method: Forty-eight children and adolescents diagnosed with autism or mental retardation accompanying with behavior disorder were treated by aripiprazole. Conners parents scale were assessed before treatment and at the end of 2nd and 4th weeks. The side effects were also observed. Results: Compared with the baseline, conduct problem, learning problem, psychosomatic disorder, impulsiveness, anxiety and hyperactive were improved significantly at the end of 2nd week ( P 〈 0. 001 ). At the end of 4th week, these symptoms were improved further. There were few side effects. Conclusion:Aripiprazole may improve the symptoms of impulsiveness and hyperactive behavior disorder in autism or mental retardation in child and adolescent and has few side effects.
出处 《临床精神医学杂志》 2007年第5期333-334,共2页 Journal of Clinical Psychiatry
关键词 阿立哌唑 儿童孤独症 精神发育迟滞 行为障碍 aripiprazole children autism mental retardatiom behavior disorder
  • 相关文献

参考文献3

  • 1Shapiro DA,Renock S,Arrington E,et al.Aripirazole,a novel atypical antipsychotic drug with a unique and robust pharmacology[J].Neuropsychopharmacology,2003,28:1400-1411.
  • 2童建明,杨正春.几种新型抗精神病药介绍[J].临床精神医学杂志,2005,15(3):182-182. 被引量:147
  • 3Findling RL,Steiner H,Weller EB.Use of antipsychotics in children and adolescent[J].J Clin Psychiatry,2005,66(Suppl 7):29-40.

二级参考文献9

  • 1黄文武,姜德国.抗精神病新药阿立哌唑[J].上海精神医学,2003,15(5):307-308. 被引量:153
  • 2久住一郎,小山司.抗精神病藥の開發動向と問題点[J].臨床精神醫學,2004,263-267.
  • 3Bowles TM, levin GM. Aripiprazole : A new atypical antipsychotic drug [ J ]. Ann pharmacother, 2003,37 : 687-694.
  • 4Murasaki M. AD-5423 versus haloperidol in the treatment of schizophrenic patients: results of the Japan multicentle, double-blind trial [ J ]. Eur Neuropsychopharmacol, 2002,12 : 5268.
  • 5Gunasekara NS, Spencer CM, Keating GM. Ziprasidone : a review of its use irt schizophrenia and schizoaffective disorder[ J ]. Drugs, 2002,62 :1217-1251.
  • 6堀澤智子,田頭利惠,藪内一輝,ほか.新規抗精神病藥SM-13496の藥理學的特性:腦内各種受容體にすと作用評價[J].日本神經精神藥理學雜志,1999,19;363.
  • 7Ogasa M,kimura T, Boylan M, et al. SM-13496 in patients with acute exacerbation of schizophrenia: a two-dosc double-blind phase Ⅱ comparison with placebo [ J ]. Schizophr Res, 2003,60 ( Suppl ) : 297.
  • 8Fleischhacker WW, Eerdekens M, Karcher k, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic[ J ]. J Chin Psychiatry, 2003,64 : 1250-1257.
  • 9孙振晓,于相芬.抗精神病药所致QTc间期延长、室速和猝死[J].国外医学(精神病学分册),2003,30(1):4-7. 被引量:21

共引文献146

同被引文献216

引证文献14

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部